Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants

Pediatric Pulmonology

Volumn 53, Issue 5, 2018, Pages 605-612

  Blanken, Maarten O ^a   Paes, Bosco ^b   Anderson, Evan J ^c   Lanari, Marcello ^d   Sheridan Pereira, Margaret ^e   Buchan, Scot ^f   Fullarton, John R ^f   Grubb, ElizaBeth ^g   Notario, Gerard ^g   Rodgers Gray, Barry S ^f   Carbonell Estrany, Xavier ^h  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MCMASTER UNIVERSITY   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Tallaght and Coombe Women's and Infant's University Hospital   (Ireland)

^f Strategen Limited   (United Kingdom)

^g ABBVIE INC   (United States)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

bronchiolitis; lower respiratory tract infection; prematurity; risk assessment; risk factors

Indexed keywords

ARTICLE; COMORBIDITY; FEMALE; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK ASSESSMENT; RISK FACTOR SCORING TOOL; SCORING SYSTEM; SEASONAL VARIATION; SENSITIVITY AND SPECIFICITY; SIBLING; AREA UNDER THE CURVE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; NEWBORN; PASSIVE SMOKING; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEASON; STATISTICAL MODEL;

AREA UNDER CURVE; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; LOGISTIC MODELS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RISK FACTORS; ROC CURVE; SEASONS; SENSITIVITY AND SPECIFICITY; TOBACCO SMOKE POLLUTION;

EID: 85045529977     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23960     Document Type: Article

References (30)

1. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017; 390:946–958.
2. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015; 372:835–845.
3. Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA, Jr. Trends in bronchiolitis hospitalizations in the United States, 2000–2009. Pediatrics. 2013; 132:28–36.
4. Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 2016; 5:417–452.
5. Palmer L, Hall CB, Katkin JP, et al. Respiratory outcomes, utilization and cost 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants. Curr Med Res Opin. 2011; 27:403–412.
6. Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012; 171:1055–1061.
7. Carbonell-Estrany X, Pérez-Yarza EG, García LS, et al. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants—the SPRING study. PLoS ONE. 2015; 10:e0125422.
8. Anderson EJ, Carbonell-Estrany X, Blanken M, et al. Burden of severe respiratory syncytial virus disease among 33-35 weeks gestational age infants born during multiple respiratory syncytial virus seasons. Pediatr Infect Dis J. 2017; 36:160–167.
9. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102:531–537.
10. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003; 143:532–540.
11. Simões EA, DeVincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis. 2015; 211:S1–S20.
12. Rezaee F, Linfield DT, Harford TJ, Piedimonte G. Ongoing developments in RSV prophylaxis: a clinician's analysis. Curr Opin Virol. 2017; 24:70–78.
13. Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L, Dutch RSV Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS ONE. 2013; 8:e59161.
14. Korsten K, Blanken MO, Nibbelke EE, Moons KG, Bont L, Dutch RSV Neonatal Network. Prediction model of RSV-hospitalization in late preterm infants: an update and validation study. Early Hum Dev. 2016; 95:35–40.
15. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004; 23:806–814.
16. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004; 23:815–820.
17. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008; 27:788–793.
18. Ambrose CS, Anderson EJ, Simões EA, et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014; 33:576–582.
19. Lanari M, Prinelli F, Adorni F, et al. Risk factors for bronchiolitis hospitalization during the first year of life in a multicentre Italian birth cohort. Ital J Pediatr. 2015; 41:40.
20. Straňák Z, Saliba E, Kosma P, et al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI). PLoS ONE. 2016; 11:e0157446.
21. Sheridan-Pereira M, Murphy J, Sloan J, et al. Respiratory syncytial virus preterm (32-36 completed weeks’ gestation) risk estimation measure for RSV hospitalization in Ireland: a prospective study. Pediatr Infect Dis J. 2016; 35:19–24.
22. Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making. 2008; 28:471–480.
23. Simões EA, Carbonell-Estrany X, Fullarton JR, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study. Respir Res. 2008; 9:78.
24. Figueras-Aloy J, Quero-Jiménez J, Fernández-Colomer B, et al. Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain. An Pediatr (Barc). 2009; 71:47–53.
25. Paes B, Steele S, Janes M, Pinelli J. Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin. 2009; 25:1585–1591.
26. Lanctôt KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin. 2008; 24:3223–3237.
27. Brubaker PH. Do not be statistically cenophobic: time to roc and roll! J Cardiopulm Rehabil Prev. 2008; 28:420–421.
28. Efron B, Tibshirani RJ. An introduction to the bootstrap. London: Chapman and Hall; 1993.
29. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013; 368:1791–1799.
30. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015; 350:g7594.